ASCO Annual Meeting: Lung Cancer

An analysis presented at 2022 ASCO reveals a potential correlation between CDKN2A/B as well as cell cycle pathway alterations and brain metastases in non–small cell lung cancer.

At a minimum follow-up of 3 years, an improvement in overall survival was seen in patients with metastatic non–small cell lung cancer treated with nivolumab and ipilimumab in combination with chemotherapy.

Results from the phase 3 PEARLS/KEYNOTE-091 trial showed improved disease-free survival with pembrolizumab vs placebo for patients with completely resected early-stage non–small cell lung cancer, without regard surgical treatment, extent of disease, or adjuvant chemotherapy.

The 5-year analysis of the phase 3 CheckMate 227 trial showed consistent, long-term survival with nivolumab plus ipilimumab for metastatic non–small cell lung cancer.

In a MET-unselected population of PD-L1–positive non–small cell lung cancer, the addition of capmatinib to pembrolizumab did not lead to more responses but increased toxicity.

The results, however, showed that remaining on mobocertinib may be warranted for patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment.

Preliminary findings of data from the phase 1/2 LUPER study demonstrate that treatment with lurbinectedin combined with pembrolizumab elicits promising efficacy in patients with metastatic small-cell lung cancer that has failed to respond to chemotherapy.

Biagio Ricciuti, MD, spoke about patients with non–small cell lung cancer with a very high PD-L1 tumor proportion score of 90% or more who were treated with first-line pembrolizumab monotherapy.

The addition of tiragolumab to atezolizumab plus carboplatin and etoposide did not yield improved overall survival or progression-free survival rates in patients with extensive-stage small cell lung cancer.

Patients with EGFR exon 20 insertion–positive non–small cell lung cancer may have antitumor response with the selective EGFR inhibitor CLN-081 following multiple prior lines of treatment.

The combination of pembrolizumab plus ramucirumab resulted in better overall survival compared with the standard of care regimens despite similar response rates, according to results of a Lung-MAP substudy presented at 2022 ASCO.

The KRAS G12C inhibitor adagrasib demonstrated an objective response rate of 43% and disease control rate of 80% among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

CancerNetwork® sat down with Jorge Nieva, MD, at the 2021 ASCO Annual Meeting to talk about the future of clinical trials for early-stage non–small cell lung cancer.

CancerNetwork® sat down with Jonathan Spicer, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about how communication across a multidisciplinary team was necessary to the success of neoadjuvant immunotherapy administration in CheckMate 816.

At ASCO 2021, CancerNetwork® spoke with Stephen Liu, MD, about his research on the ARROW trial and how these results might impact the treatment of patients with RET fusion–positive non–small cell lung cancer who are potential candidates for treatment with pralsetinib.

CancerNetwork® sat down with John Heymach, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk adjuvant immunotherapy for recurrence-free survival in resected non–small cell lung cancer.

At ASCO 2021, Stephen Liu, MD, discussed his excitement for results of the IMpower010 trial of atezolizumab in patients with early-stage resected non–small cell lung cancer

At ASCO 2021, Stephen Liu, MD, talked about treating patients with EGFR-mutant non–small cell lung cancer in the post-osimertinib setting with the combination of amivantamab and Lazertinib.

CancerNetwork® sat down with Salma Jabbour, MD, of Rutgers Cancer Institute, at 2021 ASCO to talk about what she believed was the most interesting and impactful study to come out of the meeting.

Ferdinandos Skoulidis, MD, PhD, MRCP, details what he was most excited to learn about at 2021 ASCO.

At the 2021 ASCO Annual Meeting, Stephen Liu, MD, discussed the important of findings from the ARROW trial of pralsetinib in patients with RET-altered non–small cell lung cancer.

During the 2021 ASCO Annual Meeting, Suresh S. Ramalingam, MD, looked forward to how trials regarding adjuvant therapy for early-stage non–small cell lung cancer are poised to change the treatment paradigm in this setting.

Jabbour detailed the importance of managing care in a multidisciplinary setting for patients enrolled in the KEYNOTE-799 trial with stage III NSCLC.

Among other things, Pennell focused on data regarding atezolizumab as adjuvant therapy to improve disease-free survival for patients with stage II/III resected non–small cell lung cancer.

According to data presented at the 2021 ASCO Annual Meeting, patients with crizotinib-refractory ALK-positive non–small cell lung cancer demonstrated long-term response and survival maintenance on brigatinib.

Reck mentioned the IMpower010 and CheckMate 816 trials investigating treatment options for patients with non-small cell lung cancer.

Larotrectinib’s tumor-agnostic indication for NTRK fusion–positive cancers is further validated by data presented at the 2021 ASCO Annual Meeting.

The addition of neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathological complete response rates and showed a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Although adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer, the agent did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

Patients with platinum-pretreated EGFR exon 20 insertion mutation–positive metastatic non–small cell lung cancer experienced antitumor activity with oral TKI mobocertinib, according to results presented at the 2021 ASCO Annual Meeting.